niques of photocoagulation for PSR, feeder vessel photocoagulation and scatter photocoagulation. A prospective randomised trial of feeder vessel photocoagulation for PSR demonstrated that the incidence of vitreous haemorrhage and visual loss was diminished in eyes which were treated. Since this technique of treatment is diffi cult and can be associated with choroidal neovascularisation and retinal tears, scat ter photocoagulation has also been tested. A prospective randomised trial of scatter photocoagulation for PSR demonstrated a decreased incidence of vitreous haemorr hage and visual loss in treated eyes compared to untreated eyes. No complications of scatter treatment were noted.
We presently recommend local scatter photocoagulation to areas ofPSR. In unre liable patients, we recommend 360 degrees of peripheral circumferential treatment as otherwise new seafans will develop. If scatter photocoagulation does not result in sufficient regression of the neovascularisation and vision threatening complications such as vitreous haemorrhage continue, feeder vessel treatment can be used to sup plement the scatter treatment.
The major causes of visual loss in patients with sickle cell disease are vitreous haemorrhage, traction retinal detachment and epiretinal membrane formation.! Other causes are rheg matogenous retinal detachment, exudative retinal detachment, macular ischaemia, arterial occlusions, macular hole formation and angioid streaks with macular degener ation. In an attempt to prevent visual loss from vitreous haemorrhage, traction retinal detachment, exudative retinal detachment and rhegmatogenous retinal detachment, photocoagulation has been used to close the seafan lesions of proliferative sickle cell ret inopathy (PSR). Over the last 13 years, we have performed two major randomised clini cal trials investigating the role of photocoag ulation in treating patients with proliferative sickle cell disease. This paper summarises the techniques and results of treatment.
Methods and Materials
Prospective randomised clinical trials2�5 invol ving patients with PSR were performed in Kingston, Jamaica and Chicago, Illinois. Patients with haemoglobin SC, SS, or S beta thalassaemia were included in the trials. In each of the two trials, patients with eligible bilateral proliferative retinopathy, after informed consent, had one eye assigned to photocoagulation treatment and the other eye remained untreated and served as a control. Patients with eligible unilateral proliferative retinopathy had that eye allocated to either treatment or control. In these trials, photo coagulation was performed using Xenon arc photocoagulation (Kingston portion of the feeder vessel trial)2.3 or blue/green argon laser photocoagulation (the scatter laser treatment study in Kingston5 and the feeder vessel trial in Chicago )2.4 Data were collected in each centre and the outcomes of eyes assigned to treatment and control groups were compared.
In Kingston, Jamaica, feeder vessel photo coagulation was performed following a retro bulbar anaesthetic with the application of photocoagulation bums using the O'Malley Log II Xenon arc photocoagulator. Intense spots were placed on the feeding arterioles and the draining venules from each neovas cular lesion. If subsequent fluorescein angiog raphy demonstrated that the neovascular lesion was still perfused, additional treatment was applied. An attempt was made to close all proliferative lesions in each treated eye.
In the feeder vessel study in Chicago, the Coherent Model 800 blue-green argon laser wa� used. Intense treatment spots were placed on the feeder arteriole and, after seg mentation of that vessel, the draining venule. In general, spot sizes were 500 microns, 0.2 seconds duration and with a power setting high enough to allow closure of the feeding arteriole. If the arteriolar blood column could not be segmented, then additional treatment was often performed several weeks later when thinning and pigmentation had occurred in the area of treatment.6 At this time, with :retreatment on the same spots, easier closure of the feeding arterioles was possible. Drain ing venules were closed when the arteriole had been successfully segmented. Again, an attempt was made to close all neovascular lesions in treated eyes. If additional seafan neovascular lesions developed in treated eyes, they were similarly treated.
Scatter Photocoagulation5
Patients with PSR were treated in Kingston with a localised scatter technique using the Britt Model 3250 argon blue/green laser. Grey-white 500IL spots were placed in the vicinity of the proliferative lesions. Bums were approximately one bum diameter apart and extended from one disc diameter pos terior to the lesion to one disc diameter anterior to the lesion and one clock hour to each side. Enough spots were placed to com pletely surround the neovascular lesion, but no attempt was made directly to treat the sea fan or the feeding vessels. If the lesion sub sequently remained perfused and skip areas were seen, additional treatment was often applied. If new neovascular lesions developed in a treated eye, they were similarly treated. Ophthalmic examination with fluorescein angiograms was used to determine whether neovascular lesions were larger, nonperfused, partly regressed, or unchanged.
Results
The feeder vessel photocoagulation study provided important treatment guidelines for using this technique in patients with PSR.2-4 An analysis of the untreated eyes in that study showed that there were three risk factors for the development of vitreous haemorrhage:3
(1) The presence of haemoglobin SC (as opposed to SS or SB thalassaemia). (2) Any vitreous haemorrhage in the eye at the time the patient was first seen. (3) Greater than 60 cumulative degrees of perfused neovascularisation. This study also showed that both xenon arc photocoagulation and argon laser photocoag ulation were effective in preventing the occur rence of vitreous haemorrhage. In addition, with the data from the two centers (Kingston and Chicago) combined, photocoagulation was effective in reducing visual loss from vit reous haemorrhage and the occurrence of visual loss from any cause. It was concluded that feeder vessel photocoagulation was an effective technique for preventing vitreous haemorrhage and visual loss from sickle cell disease.
A long-term follow-up of the Chicago patients from this study has recently been reported.4 Of the 44 patients originally enrolled, nearly a decade of follow-up was achieved in 22 patients. There were 15 con trol, untreated, eyes and 20 argon laser treated eyes. Prolonged loss of visual acuity was rare in both groups. Argon laser photo coagulation had a sustained effect reducing the incidence of vitreous haemorrhage and visual loss. Eight of 15 control eyes (53%) had vitreous haemorrhage and it recurred at least once in five of these eight eyes (63%). Only a single episode of vitreous haemorrhage was observed in one treated eye. Spontaneous autoinfarction of seafans was seen in four of 15 control eyes and was complete in three of these. The argon laser complications, chor oidal neovascularisation7,8 or retinal tears and detachment9 were not associated with long term visual loss. More than half of both the treated and control eyes developed new seafans.
Several factors have made feeder vessel photocoagulation a less than ideal treatment. Most retinal specialists and the vast majority of ophthalmologists·· are not familiar with the technique of feeder vessel treatment and the placement of the very intense burns requires considerable skill and experience. When these intense burns are placed, it is possible to break Bruch's membrane and cause choroidal haemorrhage or the ingrowth of choroidal neovascularisation, which is commonly seen, especially after xenon arc photocoagula tion.2-4.6-8 This can sometimes lead to further vitreous haemorrhage and visual loss, although this is rare. 4, 7, 8 In addition, we have demonstrated that with feeder vessel argon laser treatment, the progression of vitreous traction is often associated with the develop ment of retinal tears in the area of treatment. 9 Because of these problems, a scatter tech nique of treatment was devised.10-12 This treatment has been shown to be effective for retinal neovascularisation from diabetes mel litus and branch retinal vein occlusion as well as in other situations.
Prior studies suggested that scatter treat ment was effective for patients with PSR. RedmanlO in 1982 reported on local scatter treatment in 21 eyes with 45 seafans. There was complete or partial regression in 77. 8% of the seafans. Cruess and coworkers II have reported on their technique of 360 degree per ipheral circumferential scatter treatment in 40 eyes. They noticed complete or partial regres sion in 83% of eyes and in a second paper reporting 70 eyes, they noticed complete regression in 33% of the seafans and partial regression of 46%. Only 2% progressed. Again, there were no apparent complications from the treatment. Only one eye developed new seafans.
New data are now available from our ran domised trial on the effectiveness of scatter treatment.5 In 174 eyes (with a mean fol low-up of 42 months in control eyes and 47 months in the treated eyes), complete closure of the neovascularisation occurred in 30.2% of the 99 laser treated eyes and partial closure in 51%. New seafans developed in 34.3% of these eyes. In comparison, in control eyes (75 eyes), autoinfarction occurred in 22.4% of eyes and partial autoinfarction in 23.7%; new seafans developed in 41.3% of the eyes. Scat ter treatment was effective in reducing visual loss from 8.3% (control) to 3% (treated), p = .0 19. It was also effective in reducing visual loss from vitreous haemorrhage, 1 % (treated) vs. 6.7%, (control) (p= .032) and the occurrence of any vitreous haemorrhage was also reduced in the treated eyes when the data were corrected for known risk factors at entry. Although visual loss occurred in both groups from vitreous haemorrhage, epiretinal membrane formation and other mechanisms, no apparent deleterious effects of laser treat ment were seen.
The technique of scatter treatment that we have used involves only a local scatter. It is possible that 360 degrees of treatment would be more effective in preventing the develop ment of new neovascularisation, which we saw in 34.3% of the treatment eyes. We sus pect that a randomised clinical trial compar ing local scatter to 360 degree scatter would not demonstrate a difference in the outcome between the two groups since both techniques are highly effective and apparently have few side effects.
Based upon these clinical trials, our recom mendations for the therapy of PSR are as follows:
When PSR is detected, scatter treatment should be instituted. If a patient is reliable and can return for follow-up examinations on a regular basis, then a local scatter treatment should result in regression of the present neo vascular lesions. Later, if new neovascular lesions develop, then additional scatter treat ment is performed. If the patient is unreliable for follow-up, then a 360 degree technique of scatter treatment should be considered. We do not feel, at present, that all eyes with PSR should be treated with a 360 degree scatter as it is possible that this more extensive treat ment might facilitate the development of mac ular pucker and vitreous traction, important factors in visual loss in these patients. Since regression can usually be obtained with local scatter, and since the seafans that later form, if detected early, can be easily treated, we have not instituted 360 degree scatter in most patients.
In the event that the scatter treatment pro duces no regression or partial regression of a lesion and the patient continues to have prob lems, for example, repeated vitreous haemorrhage or progressive traction, then a feeder vessel technique of treatment should be considered. This therapy should then be applied directly to the feeding arterioles and draining venules from the still perfused neo vascular lesions. The presence of the scatter treatment around the neovascular lesion may be helpful in preventing retinal tears and detachment, noted previously as a complica tion of the argon laser feeder vessel technique.9
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